An evidence-based review of skin cancer rates on biologic therapies

References

• Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41–44.
   PubMedGoogle Scholar
• Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–864.
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L VVA. Long-term efficacy of biologics in dermatology. Dermatol Ther. 2009;22:22–33.
   Google Scholar
• Menter A. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. J Cutan Med Surg. 2004;8(Suppl 2):20–25.
   Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–950.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev. 2007;6:515–519.
   PubMed Web of Science ®Google Scholar
• Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–130.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–1426.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886–2895.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–432.
   PubMed Web of Science ®Google Scholar
• Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691.
   PubMed Web of Science ®Google Scholar
• Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114:587–590.
   PubMed Web of Science ®Google Scholar
• Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28:88–92.
   PubMed Web of Science ®Google Scholar
• Koo JL, Lee C, Lebwohl M, Weinstein G, Gottlieb A. Moderate-to-Severe Psoriasis, 3rd ed. New York: Informa Healthcare; 2009.
   Google Scholar
• Enbrel. (Etanercept). Prescribing information. Manufactured by Immunex Corporation. Marketed by Amgen Inc. and Pfizer Inc. Updated 2011.
   Google Scholar
• Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 Years. Arch Dermatol. 2005:861–864.
   Google Scholar
• Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011;10:289–300.
   PubMed Web of Science ®Google Scholar
• Praiser DM LC, Gordon K, leonardi CL, Gottlieb K, Tyring S, Papp KA, Short and Long-term safety profiles of etanercept in patients with psoriasis: an integrated analysis. Poster Presented at: 66th annual meeting of the American Academy of Dermatology; Poster 2618. San Antonio, Tx. 2008.
   Google Scholar
• Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol. 2001;45:528–536.
   PubMed Web of Science ®Google Scholar
• Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997;133:735–740.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, Van Der Kerkhof PC, Zitnik R, Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006;54(3 Suppl 2):S92–S100.
   Google Scholar
• Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol. 2007;157:1076–1078.
   Google Scholar
• Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009;145:94–95.
   PubMedGoogle Scholar
• Chuang GS, Wasserman DI, Byers HR, Demierre MF. Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy. J Am Acad Dermatol. 2008;59(5 Suppl):S121–S122.
   Google Scholar
• (Humira). Prescribing information. North Chicago, IL: Abbott Laboratories; 2011.
   Google Scholar
• Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863–1869.
   PubMed Web of Science ®Google Scholar
• Scotto J FT, Fraumeni JF Jr. Incidenc of non-melanoma skin cancer in the United States. Pub no (NIH) 82-2433. Bethesda, MD: US Department of Health and Human Services, Public Health Service, NIH, NCI; 1981.
   Google Scholar
• kerdel FTD, Blauvelt A, Abramovits W, Langley R, Poulin Y, Papp K, Esprit: Interim Results from a 10-year postmarketing surveillance registry for Adalimumab treatment for moderate to severe psoriasis. 69th annual meeting of American Academy of Dermatology. New Orleans, Louisiana. 2011.
   Google Scholar
• Krishna SM, Kim CN. Merkel cell carcinoma in a patient treated with adalimumab: case report. Cutis. 2011;87:81–84.
   PubMed Web of Science ®Google Scholar
• Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153:207–208.
   PubMed Web of Science ®Google Scholar
• Remicade (Infliximab) prescribing information, 1st ed. Centocor, Inc. PDR; 2010.
   Google Scholar
• Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130–2135.
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–1145.
   PubMed Web of Science ®Google Scholar
• Fulchiero GJ Jr. Salvaggio H, Drabick JJ, Staveley-O'Carroll K, Billingsley EM, Marks JC, Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 Suppl):S65–S67.
   Google Scholar
• Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology. 2010;221:9–12.
   PubMed Web of Science ®Google Scholar
• Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma. Hautarzt. 2009;60:655–657.
   Google Scholar
• Amevive (Alefacept) Prescribing information, 1st ed. Astellas, Inc. PDR; 2010.
   Google Scholar
• krell J BJ, Coynik D. Assessment and tracking of long term alefacept safety (ATLAS): analysis of data from approximately 1,200 patients [abstract]. J Am Acad Dermatol. 2007;56 (2 Suppl 2): AB191.
   Google Scholar
• Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204–214.
   PubMed Web of Science ®Google Scholar
• Stelara. (ustekinumab) prescribing information, Centocor, Inc. Revised October 2010.
   Google Scholar
• Papp K HV, Yeilding N, Gordon N, Szapary P, Li S, Kreuger G, Maligancies in ustekinumab-treated psoriasis patients: observations with up to 3 years of follow-up and comparisons to the general US population [poster]. Society of Investigative Dermatology Annual Meeting. Atlanta, Goergia. 2010.
   Google Scholar
• Reich K LC, Griffiths CEM, Szapary PO, WAsfi Y, Hsu MC, Gordon K. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. 22nd World Congress of Dermatology. Seoul, Korea. 2011.
   Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408.
   PubMed Web of Science ®Google Scholar
• Marmenout A, Fransen L, Tavernier J, Van Der Heyden J, Tizard R, Kawashima E, Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem. 1985;152:515–522.
   PubMedGoogle Scholar
• Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998;10:573–580.
   PubMed Web of Science ®Google Scholar
• Muller U, Jongeneel CV, Nedospasov SA, Lindahl KF, Steinmetz M. Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex. Nature. 1987;325:265–267.
   PubMed Web of Science ®Google Scholar
• Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 1996;16:1–11.
   PubMed Web of Science ®Google Scholar
• Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461–465.
   PubMed Web of Science ®Google Scholar
• Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–416.
   PubMed Web of Science ®Google Scholar
• Malik ST, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer. 1989;44:918–925.
   PubMed Web of Science ®Google Scholar
• Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993;177:1391–1398.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–465.
   PubMed Web of Science ®Google Scholar
• Maeda A, Schneider SW, Kojima M, Beissert S, Schwarz T, Schwarz A. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res. 2006;66:2962–2969.
   PubMed Web of Science ®Google Scholar
• Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211–216.
   PubMed Web of Science ®Google Scholar
• Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101–113.
   PubMed Web of Science ®Google Scholar
• Nelson RP Jr. Ballow M. 26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol. 2003;111(2 Suppl):S720–S743.
   PubMedGoogle Scholar
• Penn I. Overview of the problem of cancer in organ transplant recipients. Ann Transplant. 1997;2:5–6.
   Google Scholar
• Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59–67.
   PubMedGoogle Scholar
• Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953–956.
   PubMed Web of Science ®Google Scholar
• Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144:97–99.
   PubMedGoogle Scholar